Independent Market Access and Reimbursement Risk Assessment.
Built by former payers, HTA reviewers, and Industry Experts.
Why this document exists A medicine can be approved by regulators and still fail commercially, because the public bodies and insurers who pay for medicines apply their own, separate test.
Summary Contingent value rights (CVRs) — conditional payments tied to regulatory approval, reimbursement milestones, or sales thresholds — have become standard practice in pharma and biotech acquisitions, with their use
How Evidence Quality Scores Impact HTA Assessment Success: The 2.9 Benchmark Since 2020, assets with an average Evidence Quality score of 2.9 have sailed through HTA assessments more regularly than
About MARA Rating: We provide an independent Market‑Access Risk Assessment (A++ → C) built on a transparent, 10‑domain HTA framework. Use the score to benchmark an asset’s access prospects against
MARA Rating in the Workflow: How Market Access & BD Teams Use It to Make Better Asset Calls (MARA Rating stands for Market Access Risk Assessment Rating.) Most valuations overweight
Brensocatib, poised for its first FDA decision in non-cystic fibrosis bronchiectasis, shows clear clinical benefits but faces major U.S. market access challenges. We examine Phase 3 ASPEN trial results, safety
A concise overview of the essential Health Technology Assessment domains every drug developer must address. Use this checklist to design and execute development programs that directly address payer needs across